mTOR/HDAC-IN-1 HCl is a potent dual inhibitor of mTOR and HDAC with potential anti-inflammatory, anti-proliferative, autophagy and apoptosis-inducing effects for cancer research.

HDAC-IN-52 is a pyridine-containing HDAC inhibitor that inhibits HDAC1, HDAC2, HDAC3 and HDAC10 with IC50s of 0.189, 0.227, 0.440 and 0.446 μM, respectively. HDAC-IN-52 can be used in cancer research.

HDAC8-IN-20a (HDAC8 inhibitor-20a) is a potent and selective HDAC8 inhibitor with an IC50 of 27 nM. HDAC8-IN-20a blocks activation of growth receptor survival signals.

HDAC-IN-7 (HBI-8000) (Chidamide impurity) is an impurity of Chidamide. Chidamide is a potent and orally bioavailable inhibitor of HDAC enzymes class I (HDAC1/2/3) and class IIb (HDAC10).

HDAC-IN-57 is an orally active pan-inhibitor of histone deacetylase (HDAC), inhibiting HDAC1, HDAC2, HDAC6, and HDAC8 with IC50 values of 2.07 nM, 4.71 nM, 2.4 nM, and 107 nM, respectively. HDAC-IN-57 inhibits LSD1 with an IC50 value of 1.34 μΜ. HDAC-IN-57 has anti-tumor activity and can induce apoptosis.

HDAC-IN-51 is an HDAC inhibitor.

HDAC6 degrader 9c is a small molecule histone deacetylase 6 (HDAC6) degrader that can be used to study cancer or other diseases.

(2E)-N-(4-methoxyphenyl)-3-[3-(4-methylphenyl)-1-phenyl-1H-pyrazol-4-yl]prop-2-enamide is a compound used as a molecular structural unit.

mTOR/HDAC-IN-1 (Compound 50) is a dual inhibitor targeting both mTOR and HDAC with respective IC50 values of 0.49 nM and 0.91 nM. It holds potential as an anti-cancer agent [1].This compound is unstable in powder form and other related salt forms are recommended.

HDAC-IN-4 is a selective HDAC6 and HDAC10 inhibitor (pIC50s: 7.2 and 6.8 in BRET assay) with antitumoral activity.

VEGFR2/HDAC1-IN-1 (compound 13) is a potent dual inhibitor of VEGFR-2 and HDAC, with IC50 values of 57.83 nM for VEGFR-2 and 9.82 nM for HDAC. It arrests the cell cycle at the S and G2 phases and induces apoptosis in HeLa cells, demonstrating an anti-angiogenic effect [1].

HDAC6-IN-25 (compound 8) is a potent and selective HDAC6 inhibitor, exhibiting an IC50 value of 0.6 nM [1].

HDAC6-IN-21 (compound 13) is an irreversible inhibitor of histone deacetylase 6 (HDAC6) [1].

HDAC6-IN-24 (compound N1) is an inhibitor of histone deacetylase 6 (HDAC6) [1].

HDAC1/CDK7-IN-1 (compound 8e) serves as a dual inhibitor targeting both CDK7 and HDAC1, with IC50 values of 893 nM and 248 nM , respectively. This compound effectively suppresses the proliferation of various cancer cell lines, including MDA-MB-231, MCF-7, A549, and HCT-116. Additionally, it triggers cell cycle arrest and apoptosis in HCT-116 cells and impedes their migration [1].

ACY-957 (HDAC Inhibitor C001) is an orally active and selective inhibitor of HDAC1 and HDAC2 (IC50s: 7 nM, 18 nM, and 1300 nM against HDAC1/2/3) and shows no inhibition on HDAC4/5/6/7/8/9.

HDAC-IN-64 (Compound 13), an HDAC inhibitor, demonstrates potent inhibition of HDAC4/5/6/7/9 with IC50 values of 24, 45, 85, 31, and 37 nM, respectively. It exhibits anti-proliferative and anti-migration effects on prostate cancer (PCA) cells, specifically inhibiting the growth of LNCaP and RWPE-1 cells with GI50 values of 0.32 and 1.1 μM, respectively [1].

Compound A5b, also known as JMJD3/HDAC-IN-1, is a dual inhibitor that targets both JMJD3 (Jumonji domain-containing protein demethylase 3) and HADC1 (histone deacetylase, IC50 = 16 nM). It induces hypermethylation of histone H3K27 and hyperacetylation of H3K9, while also promoting apoptosis through the cleavage of caspase-7 and PARP. This compound has demonstrated the ability to effectively inhibit cancer cell cloning, migration, and invasion [1].

CDK/HDAC-IN-3 is an orally active dual inhibitor of HDACs and CDKs, offering potent and selective inhibition of CDK9, CDK12, CDK13, HDAC1, HDAC2, and HDAC3, with IC50 values of 98.32 nM, 98.85 nM, 100 nM, 62.12 nM, 93.28 nM, and 82.87 nM, respectively. This compound is applicable in the treatment of acute myeloid leukemia (AML) [1].

HDAC ligand-1 is a synthetic precursor utilized in the production of PROTAC-based HDAC degraders [1].

HDAC/JAK/BRD4-IN-1 (compound 25ap) is a potent triple inhibitor targeting HDAC, JAK, and BRD4. This compound not only inhibits cell proliferation but also induces apoptosis in MDA-MB-231 cells and demonstrates in vivo anticancer efficacy [1].

HDAC/CD13-IN-1 (Compound 12) is an inhibitor of both HDAC and CD13, with IC50 values of 0.34 μM for hCD13, 0.53 μM for porcine CD13, and 0.03, 0.06, and 0.02 μM for HDAC1, HDAC2, and HDAC3, respectively. This compound effectively suppresses the proliferation of MV4-11, K562, Jeko-1, and HL60 cancer cells, with IC50 ranges between 0.25-2.04 μM, and also induces apoptosis in these cells. Furthermore, HDAC/CD13-IN-1 demonstrates capabilities in hindering metastasis and invasion [1].

HDAC-IN-41 (Compound 7c) is an orally active, selective class I HDAC inhibitor that acts on HDAC1 (IC50: 0.62 μM), HDAC2 (IC50: 1.46 μM) and HDAC3 (IC50: 0.62 μM). HDAC-IN-41 shows NO-releasing activity.

HDAC-IN-20 is used as an HDAC inhibitor that acts by preventing HDAC-mediated diseases.

HDAC-IN-35 (Compound 14) is an effective and selective inhibitor of VEGFR-2 and HDAC, with IC50 values of 13.2 and 0.166 μM for VEGFR-2 and HDAC6, respectively.

A2AAR/HDAC-IN-2 is a potent dual A2AAR/HDAC inhibitor.A2AAR/HDAC-IN-2 shows good affinity for A2AAR (Ki:10.3 nM) and inhibits HDAC1 well (IC50:18.5 nM). A2AAR/HDAC-IN-2 can be used in anti-tumour studies.

HDAC/BET-IN-1 is a chemical compound exhibiting submicromolar inhibitory activity against HDAC1 and HDAC6, with IC50 values of 0.163 μM and 0.067 μM, respectively, and against BRD4, with a Ki of 0.076 μM. Additionally, it possesses potent antileukemia activity.

HDAC-IN-49 is a potent, non-selective inhibitor of HDAC (HDAC), demonstrating IC50 values of 13 nM for HDAC1, 14 nM for HDAC2, 21 nM for HDAC3, 1880 nM for HDAC4, and 10 nM for HDAC6. This compound exhibits significant antileukemic activity while maintaining low cytotoxicity towards healthy cells.

HDAC-IN-30 is a multi-target HDAC inhibitor. HDAC-IN-30 inhibits HDAC1 (IC50 =13.4 nM), HDAC2 (IC50 =28.0 nM), HDAC3 (IC50 =9.18 nM), HDAC6 (IC50 =42.7 nM), HDAC8 (IC50 =131 nM). HDAC-IN-30 shows potent antitumor efficacy.

HDAC-IN-31 is a selective, potent, orally active HDAC inhibitor that acts on HDAC1 (IC50: 84.90 nM), HDAC2 (IC50: 168.0 nM), HDAC3 (IC50: 442.7 nM), HDAC8 (IC50>10000 nM). HDAC-IN-31 has good anti-tumour effects. HDAC-IN-31 has shown potential research value in diffuse large B-cell lymphoma.

PI3K/HDAC-IN-2 is a potent dual PI3K/HDAC inhibitor, capable of acting on PI3Kα (IC50: 226 nM), PI3Kβ (IC50: 279 nM), PI3Kγ (IC50: 467 nM), PI3Kδ (IC50: 29 nM), HDAC1 (IC50: 1.3 nM), and PI3K/HDAC-IN-2 is PI3Kδ and class I and IIb HDAC selective and exhibits significant anticancer effects.

HDAC-IN-36 is an orally active HDAC (histone deacetylase) inhibitor with an IC50 value of 11.68 nM for HDAC6. HDAC-IN-36 induces apoptosis, autophagy and inhibits migration. HDAC-IN-36 exhibits antitumor and antimetastatic effects and can be used to study breast cancer. HDAC-IN-36 exhibits antitumor and antimetastatic effects and can be used to study breast cancer.

HDAC-IN-27 is a potent and orally active inhibitor of HDAC Class I (0.43 nM - 3.01 nM for HDAC1-3). HDAC-IN-27 shows activity against anti-acute myeloid leukemia (AML).

HDAC/Top-IN-1 is a broad-spectrum, orally active dual HDAC/Top inhibitor that acts on HDAC1 (IC50: 0.036 μM), HDAC2 (IC50: 0.14 μM), HDAC3 (IC50: 0.059 μM), HDAC6 (IC50: 0.089 μM) and HDAC8 ( IC50: 9.8 μM). HDAC/Top-IN-1 was able to block HEL cells in S-phase and effectively induce apoptosis.

HDAC-IN-26 is a highly selective class I HDAC inhibitor with an EC 50 value of 4.7 nM.

PARP-1/HDAC-IN-1 is an effective dual inhibitor of PARP-1/HDAC6, with IC50 of 68.90 nM and 510 nM respectively. PARP-1/HDAC-IN-1 has anti-cancer, anti-migration and anti-angiogenesis activities.

HDAC-IN-3 (GSK3117391A) is a potent histone deacetylase (HDAC) inhibitor, and treatment chronic inflammatory disorders.

HDAC-IN-55(8j) is a small-molecule inhibitor that enhances E-cadherin expression and suppresses cancer cell proliferation [1].

HDAC-IN-59 (compound 13a), a potent histone deacetylase (HDAC) inhibitor, enhances intracellular reactive oxygen species (ROS) production, induces DNA damage, arrests the cell cycle at the G2/M phase, and triggers the mitochondrial apoptotic pathway, leading to cell apoptosis [1].

Tubulin/HDAC-IN-2 (Compound II-19k) is a dual inhibitor targeting Tubulin and HDAC, exhibiting IC50 values of 0.403 μM for HDAC1, 0.591 μM for HDAC2, 3.552 μM for HDAC3, and 0.459 μM for HDAC6. The compound induces G2 phase cell cycle arrest and promotes apoptosis. It effectively hampers the proliferation of both hematoma and solid tumor cells, diminishes tumor metastasis, and demonstrates tumor growth inhibition in a liver tumor allograft mouse model [1].

HDAC6 degrader-1, a proteolysis-targeting chimeric molecule (PROTAC), incorporates the selective HDAC6 inhibitor Nexturastat A (Nex A) for HDAC6 binding, a linker, and an E3 ligase recruiting ligand. This compound effectively induces HDAC6 degradation, displays superior selectivity over other HDAC isoforms, and efficiently inhibits cell proliferation [1].

HDAC-IN-42 (compound 14f) is a highly potent and selective inhibitor of histone deacetylase (HDAC) enzymes, with IC50 values of 0.19 μM for HDAC1 and 4.98 μM for HDAC6. It exhibits remarkable anticancer properties and inhibits cell proliferation. Additionally, HDAC-IN-42 induces apoptosis and causes cell cycle arrest specifically at the G2/M phase [1].

MAO A/HDAC-IN-1 is an effective monoamine oxidase A (MAO A) and HDAC dual inhibitor, which can be used for glioma research.

HDAC-IN -45, a small molecule HDAC inhibitor, was able to form hydrogen bonds with Y303 residues and exhibited anticancer effects. HDAC-IN-45 significantly inhibited HDAC1, HDAC2 and HDAC3 subtypes with their IC50 values of 0.108, 0.585 and 0.563 μM, respectively.

HDAC3 inhibitor is an allosteric inhibitor of histone deacetylase 3 (HDAC3; Ki = 0.16 nM). It is selective for HDAC3 over HDAC1 and HDAC2 (IC50s = 0.95, 11.81, and 95.45 nM, respectively, using recombinant HDACs). In addition, it is selective for acute myeloid, monocytic, and lymphoblastic leukemia cell lines (EC50s = 36.37, 76.64, and 151.7 nM, respectively) over chronic myeloid, acute promyelocytic, and acute lymphoblastic cells (EC50s = 2,160, >10,000, and >10,000 nM, respectively).

SHP2/HDAC-IN-1, a dual allosteric inhibitor targeting SHP2 and HDAC, exhibits potent inhibitory effects with IC 50 values of 20.4 nM (SHP2) and 25.3 nM (HDAC1), respectively. This compound activates T cells, enhances antigen presentation, and promotes cytokine secretion, facilitating efficient antitumor immunity. It holds potential for cancer immunotherapy research.

c-Met/HDAC-IN-2 is a potent dual inhibitor of c-Met and HDAC, exhibiting IC50 values of 5.40 nM for c-Met and 18.49 nM for HDAC1, respectively. It demonstrates antiproliferative effects on various cancer cell lines, induces G2/M-phase arrest, and triggers apoptosis in HCT-116 cells, making it a promising candidate for anti-cancer resistance research.

PDE5/HDAC-IN-1 is a potent inhibitor of phosphodiesterase 5 (PDE5) and HDAC, with IC50 values of 46.3 nM and 14.5 nM, respectively.

HDAC-IN-37 is a potent inhibitor of HDAC, acting on HDAC1 (IC50: 0.0551 μM), HDAC3 (IC50: 1.24 μM), HDAC8 (IC50: 0.948 μM) and HDAC6 (IC50: 34.2 μM). HDAC-IN-37 is able to slowly induce histone acetylation. HDAC-IN-37 prevents the transition from G1 to S phase and induces early apoptosis.